USP acquires Pharmatech Associates

United States Pharmacopeia is acquiring Pharmatech Associates. USP said the acquisition is being undertaken to extend services that help manufacturers meet global quality standards across the drug and product lifecycle.

“The drug recalls we’ve seen in recent years and the supply chain challenges underscored by the COVID-19 pandemic have raised concerns about ongoing quality and safety issues,” said Ronald Piervincenzi, USP’s CEO. “This announcement positions us to continue to strengthen the supply chain and extend our many years of collaborating with global regulators and manufacturers to ensure the quality of medicines as we have done with our donor-funded work and ingredient verification services for API and excipients.”

“We are pleased to share with USP the goal of helping manufacturers to bring safe and effective treatments to patients who need them.  We bring a high standard of service to our clients, grounded in scientific excellence, and designed to meet the future compliance, quality, and business performance needs of the global healthcare industry,” said Bikash Chatterjee, CEO and chairman, Pharmatech Associates.

Pharmatech Associates and its employees will continue day-to-day operations independent of USP.